Search Result

Results for "

HGFs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin Receptor (2) Apoptosis (5) Bacterial (1) c-Met/HGFR (27) Caspase (1) Endogenous Metabolite (1) MARK (1) mRNA (1) Phosphatase (1) Prostaglandin Receptor (2) Reference Standards (2) Ser/Thr Protease (1) SHP1 (1) SHP2 (1) Small Interfering RNA (siRNA) (3) VD/VDR (2) VEGFR (1)
By Research Areas:	Cancer (28) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (6) Metabolic Disease (5) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) mRNA (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1415A

Norleual TFA 1 Publications Verification	c-Met/HGFR Angiotensin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual TFA is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .

HY-137455

Terevalefim ANG-3777	c-Met/HGFR	Inflammation/Immunology
Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor .

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the *HGF/c-Met* signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .

HY-106961

ONO 1301 ONO-AP 500-02	Prostaglandin Receptor	Cardiovascular Disease
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-P991589

SFN68 NOV-1105	c-Met/HGFR	Cancer
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting *HGF. SFN68 significantly inhibits HGF/c-Met* interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .

HY-P1415

Norleual	c-Met/HGFR Angiotensin Receptor	Neurological Disease Metabolic Disease
Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .

HY-P991565

CE-355621	c-Met/HGFR	Cancer
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (K_D = 200 pM, IC₅₀ = 466 pM) in A549 cells and cyno c-Met (K_D = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .

HY-106961A

(Z)-ONO 1301 (Z)-ONO-AP 500-02	Prostaglandin Receptor	Cardiovascular Disease
(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .

HY-RS06152

HGF Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HGF Human Pre-designed siRNA Set A contains three designed siRNAs for HGF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HGF Human Pre-designed siRNA Set A HGF Human Pre-designed siRNA Set A

HY-RS22936

Hgf Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Hgf Rat Pre-designed siRNA Set A contains three designed siRNAs for Hgf gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hgf Rat Pre-designed siRNA Set A Hgf Rat Pre-designed siRNA Set A

HY-RS16504

Hgf Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Hgf Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hgf gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hgf Mouse Pre-designed siRNA Set A Hgf Mouse Pre-designed siRNA Set A

HY-P99217

Rilotumumab AMG 102	c-Met/HGFR	Cancer
Rilotumumab (AMG 102) is an *anti-HGF* (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .

HY-174670

*Human HGF* mRNA**	mRNA	Cancer
Human HGF mRNA encodes the human hepatocyte growth factor (HGF) protein, a protein that binds to the hepatocyte growth factor receptor to regulate cell growth, cell motility and morphogenesis in numerous cell and tissue types. It also plays a role in angiogenesis, tumorogenesis, and tissue regeneration.

HY-P99192

Emibetuzumab LY2875358	c-Met/HGFR	Cancer
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both *HGF*-dependent and *HGF*-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .

HY-145263

VD2173	Ser/Thr Protease	Cancer
VD2173 is a side chain cyclized macrocyclic peptide inhibitor of HGF-activating serine proteases. VD2173 potently inhibits matriptase and hepsin. VD2173 can be used for the research of lung cancer .

HY-P990949

Umikibart YYB-101; ABX101	c-Met/HGFR	Inflammation/Immunology
HY-P990949 is an *HGF*-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99250

Onartuzumab 1 Publications Verification MetMAb	c-Met/HGFR	Cancer
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .

HY-N13286

Glycozolidal	Bacterial	Infection
Glycozolidal (compound 12) is a carbazole alkaloid with antibacterial activity against P. gingivalis. Glycozolidal is cytotoxic against human gingival fibroblasts (HGFs) and monocytes (U937) in vitro with IC₅₀ values of 120.86 µg/mL and 97.74 µg/mL, respectively .

HY-154988

MARK4 inhibitor 4	MARK	Neurological Disease Cancer
MARK4 inhibitor 4 is a MARK4 inhibitor with an IC₅₀ of 1.49 μM. MARK4 inhibitor 4 can be used in cancer and tau lesion-related research .

HY-P99391

Telisotuzumab ABT-700	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-114363A

SRI 31215 TFA 2 Publications Verification	c-Met/HGFR	Cancer
SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC₅₀ values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer .

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-16969

Dihexa 5 Publications Verification PNB-0408; N-hexanoic-Try-Ile-(6)-amino hexanoic amide; Hexanoyl-Tyr-Ile-Ahx-NH2	c-Met/HGFR	Neurological Disease
Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (K_d=65 pM) and potentiates its activity at its receptor, c-Met. Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models. Dihexa may have therapeutic potential as a treatment Alzheimer’s disease .

HY-120159

GS-493	SHP2 SHP1 Phosphatase	Cancer
GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC₅₀ of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity .

HY-10338A

Foretinib phosphate	c-Met/HGFR VEGFR	Cancer
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .

HY-P991660

ARGX-111	c-Met/HGFR	Cancer
ARGX-111 is an afucosylated anti-MET antibody. ARGX-111 blocks HGF-dependent and -independent signaling, downregulating MET expression on the tumor cell surface. ARGX-111 depletes MET-expressing circulating tumor cells through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thereby inhibiting tumor metastasis. ARGX-111 depletes circulating tumor cells and inhibits bone and lung metastasis in an orthotopic mouse model of metastatic breast cancer. ARGX-111 is promising for research in breast cancer and other cancers .

HY-18696

AMG-337 1 Publications Verification	c-Met/HGFR Caspase Apoptosis	Cancer
AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC₅₀ values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis .

HY-E70754

MET Y1230A Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230A is a mutant of MET. MET Y1230A Recombinant Human Active Protein Kinase is a recombinant MET Y1230A protein that can be used to study MET Y1230A-related functions .

HY-E70756

MET Y1230D Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230D is a mutant of MET. MET Y1230D Recombinant Human Active Protein Kinase is a recombinant MET Y1230D protein that can be used to study MET Y1230D-related functions .

HY-E70758

MET Y1235D Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1235D is a mutant of MET. MET Y1235D Recombinant Human Active Protein Kinase is a recombinant MET Y1235D protein that can be used to study MET Y1235D-related functions .

HY-E70749

MET D1228N Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228N is a mutant of MET. MET D1228N Recombinant Human Active Protein Kinase is a recombinant MET D1228N protein that can be used to study MET D1228N-related functions .

HY-E70748

MET D1228H Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228H is a mutant of MET. MET D1228H Recombinant Human Active Protein Kinase is a recombinant MET D1228H protein that can be used to study MET D1228H-related functions .

HY-E70755

MET Y1230C Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230C is a mutant of MET. MET Y1230C Recombinant Human Active Protein Kinase is a recombinant MET Y1230C protein that can be used to study MET Y1230C-related functions .

HY-E70752

MET L1195V Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET L1195V is a mutant of MET. MET L1195V Recombinant Human Active Protein Kinase is a recombinant MET L1195V protein that can be used to study MET L1195V-related functions .

HY-E70757

MET Y1230H Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230H is a mutant of MET. MET Y1230H Recombinant Human Active Protein Kinase is a recombinant MET Y1230H protein that can be used to study MET Y1230H-related functions .

HY-E70753

MET M1250T Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET M1250T is a mutant of MET. MET M1250T Recombinant Human Active Protein Kinase is a recombinant MET M1250T protein that can be used to study MET M1250T-related functions .

HY-E70750

MET F1200I Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET F1200I is a mutant of MET. MET F1200I Recombinant Human Active Protein Kinase is a recombinant MET F1200I protein that can be used to study MET F1200I-related functions .

HY-B2176R

ATP (Standard) Adenosine 5'-triphosphate (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
ATP (Standard) is the analytical standard of ATP. This product is intended for research and analytical applications. ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation . In Vitro: ATP (5 mM; 1 hour) co-treatment with LPS (1 μg/mL) has a synergistic effect on the activation of the NLRP3 inflammasome in HGFs . ATP (2 mM; 0.5-24 hours) induces secretion of IL-1β, KC and MIP-2 from BMDMs in a caspase-1 activation-dependent manner . ATP promotes neutrophil chemotaxis in vitro . In Vivo: ATP (50 mg/kg; i.p.) protects mice against bacterial infection in vivo . ATP induces the secretion of IL-1β, KC and MIP-2 and neutrophils recruitment in vivo .

HY-A0020

Eldecalcitol 3 Publications Verification ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3	VD/VDR Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .

HY-A0020R

Eldecalcitol (Standard) ED-71 (Standard); 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3 (Standard)	Reference Standards VD/VDR Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Eldecalcitol (Standard) is the analytical standard of Eldecalcitol. This product is intended for research and analytical applications. Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .

Norleual TFA 1 Publications Verification	c-Met/HGFR Angiotensin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual TFA is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .

Norleual	c-Met/HGFR Angiotensin Receptor	Neurological Disease Metabolic Disease
Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .

Cat. No.	Product Name	Target	Research Area